BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 21756809)

  • 1. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
    Gu X; Jia S; Wei W; Zhang WH
    Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil.
    Li JJ; Di GH; Tang LC; Yu KD; Hu Z; Liu GY; Lu JS; Wu J; Han QX; Shen ZZ; Shao ZM
    Breast J; 2011; 17(6):657-60. PubMed ID: 21933300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant chemotherapy for primary breast cancer].
    Li JF; Ouyang T; Wang TF; Lin BY
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
    Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
    Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
    Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
    Lin XG; Xie DR; Yao HR; Li ZH; Jiang ZM; Liu TH
    Ai Zheng; 2003 Apr; 22(4):411-4. PubMed ID: 12704001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
    Wang B; Fu JF; Hong ZW
    Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
    Hui R; Zhang M; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
    Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.